Memantina Generis

Memantine, the active ingredient in Memantina Generis, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for patients with moderate to severe Alzheimer’s disease, where it may help maintain daily living activities and slow cognitive decline.

GNH USA supplies Memantina Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and timely delivery across multiple continents.

Memantine, an NMDA receptor antagonist, is used in the management of Alzheimer’s disease, a progressive neurodegenerative disorder that impairs memory, reasoning and daily activities.

- Moderate to severe Alzheimer’s disease: improves cognition and daily functioning in adult patients. - Mild to moderate Alzheimer’s disease (as adjunct to cholinesterase inhibitors): may support cognitive performance. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression in some individuals.

Common Side Effects: - Dizziness: transient light‑headedness, especially at treatment initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, manageable with diet or laxatives. - Confusion: occasional disorientation, typically improves over time.

Serious or Rare Side Effects: - Seizures: rare but may occur, requiring immediate medical attention. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hallucinations or psychosis: uncommon, may necessitate discontinuation.

Memantine should be used with caution in patients with the following considerations: - Renal impairment: dose adjustment may be required. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: observe blood pressure and heart rate. - Concomitant use with other NMDA antagonists: avoid additive neurotoxicity. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Memantine may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Other NMDA antagonists (e.g., ketamine): additive central nervous system effects. - High‑dose anticholinergics: may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, barbiturates): enhanced sedation. - Loop diuretics (e.g., furosemide): possible elevation of memantine plasma levels. - Antihypertensive agents: potential for exaggerated blood pressure changes.